CEL-SCI CORPORATION Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales
CEL-SCI CORPORATION (CVM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales of $0 for the 12-month period ending 2023-09-30, per its 10-K filed 2023-12-21.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales · last filed 2023-12-21
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for the quarter ending 2023-09-30 was $0.00.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for the quarter ending 2023-06-30 was $0.00.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for the quarter ending 2023-03-31 was $0.00.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for fiscal 2022 was $70.59K, a 98.25% decline from fiscal 2021.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for fiscal 2021 was $4.02M.
- CEL-SCI CORPORATION fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, sales for fiscal 2020 was -$3.07M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-21 | $0.00 derived: sum of 2 quarters · filed 2023-12-21 | $0.00 derived: sum of 3 quarters · filed 2023-12-21 | $0.00 10-K · filed 2023-12-21 | |
| 2023-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-10 | $0.00 derived: sum of 2 quarters · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 4 quarters · filed 2023-12-21 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 | $0.00 10-Q · filed 2023-05-12 | $0.00 derived: sum of 3 quarters · filed 2023-12-21 | $0.00 derived: sum of 4 quarters · filed 2023-12-21 | |
| 2022-12-31 | $0.00 10-Q · filed 2023-02-14 | $0.00 derived: sum of 2 quarters · filed 2023-12-21 | $0.00 derived: sum of 3 quarters · filed 2023-12-21 | $0.00 derived: sum of 4 quarters · filed 2023-12-21 | |
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-21 | $0.00 derived: sum of 2 quarters · filed 2023-12-21 | $0.00 derived: sum of 3 quarters · filed 2023-12-21 | $70.59K 10-K · filed 2023-12-21 | |
| 2022-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-10 | $0.00 derived: sum of 2 quarters · filed 2023-08-10 | $70.59K 10-Q · filed 2023-08-10 | $7.93M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-12 | $70.59K 10-Q · filed 2023-05-12 | $7.93M derived: sum of 3 quarters · filed 2023-05-12 | $7.68M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $70.59K 10-Q · filed 2023-02-14 | $7.93M derived: sum of 2 quarters · filed 2023-02-14 | $7.68M derived: sum of 3 quarters · filed 2023-02-14 | $4.14M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-09-30 | $7.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-27 | $7.61M derived: sum of 2 quarters · filed 2022-12-27 | $4.06M derived: sum of 3 quarters · filed 2022-12-27 | $4.02M 10-K · filed 2022-12-27 | -$4.02M 10-K · filed 2021-12-21 |
| 2021-06-30 | -$247.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-13 | -$3.80M derived: sum of 2 quarters · filed 2021-08-13 | -$3.84M 10-Q · filed 2021-08-13 | -$3.87M derived: sum of 4 quarters · filed 2021-12-21 | |
| 2021-03-31 | -$3.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-17 | -$3.59M 10-Q · filed 2021-05-17 | -$3.63M derived: sum of 3 quarters · filed 2021-12-21 | -$9.21M derived: sum of 4 quarters · filed 2021-12-21 | |
| 2020-12-31 | -$41.85K 10-Q · filed 2021-02-12 | -$78.30K derived: sum of 2 quarters · filed 2021-12-21 | -$5.66M derived: sum of 3 quarters · filed 2021-12-21 | -$3.11M derived: sum of 4 quarters · filed 2021-12-21 | |
| 2020-09-30 | -$36.45K derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-12-21 | -$5.62M derived: sum of 2 quarters · filed 2021-12-21 | -$3.07M derived: sum of 3 quarters · filed 2021-12-21 | -$3.07M 10-K · filed 2021-12-21 | |
| 2020-06-30 | -$5.58M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2020-12-31 | -$3.04M derived: sum of 2 quarters · filed 2020-12-31 | -$3.04M 10-Q/A · filed 2020-12-31 | -$8.01M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2020-03-31 | $2.55M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2020-12-30 | $2.55M 10-Q/A · filed 2020-12-30 | -$2.43M derived: sum of 3 quarters · filed 2021-05-17 | -$525.24K derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | $0.00 10-Q/A · filed 2020-12-30 | -$4.97M derived: sum of 2 quarters · filed 2021-05-17 | -$3.07M derived: sum of 3 quarters · filed 2021-05-17 | -$3.07M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-09-30 | -$4.97M derived: 10-Q 12 month − 10-Q 9 month · filed 2021-05-17 | -$3.07M derived: sum of 2 quarters · filed 2021-05-17 | -$3.07M derived: sum of 3 quarters · filed 2021-05-17 | -$3.07M 10-Q · filed 2021-05-17 | $3.59M 10-Q · filed 2020-02-10 |
| 2019-06-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-14 | $1.90M derived: sum of 2 quarters · filed 2019-08-14 | $1.90M 10-Q · filed 2019-08-14 | ||
| 2019-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-14 | $0.00 10-Q · filed 2019-05-14 | |||
| 2018-12-31 | $0.00 10-Q · filed 2019-02-14 | ||||
| 2018-09-30 | $595.78K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |